ArticleTurkish journal of medical sciences2025
Effects of empagliflozin on cyclophosphamide-induced neurotoxicity in rats without diabetes.
Article in Turkish journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring the Effects of Empagliflozin Administration and Physical Training on Cognitive Functions in an Amyloid Beta-Induced Alzheimer's Rat Model.Current medicinal chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/aim: The objective of this study was to evaluate the effects of empagliflozin on cyclophosphamide-induced neurotoxicity in rats. Materials and methods: A total of 32 male Wistar rats were separated into 4 groups with 8 rats in each: the control group, cyclophosphamide group, empagliflozin group, and cyclophosphamide plus empagliflozin group. At the end of the experiment the rats' brains were removed for biochemical analysis of oxidative stress parameters (malondialdehyde, total sulfhydryl, total oxidant status, and total antioxidant capacity) and histopathological analysis. Results: Total sulfhydryl levels were increased in the empagliflozin group and empagliflozin and cyclophosphamide group compared to the cyclophosphamide group but histopathological findings were not improved. Furthermore, when empagliflozin treatment was used coupled with cyclophosphamide, necrosis was significantly higher. Conclusion: Empagliflozin has no protective effect on cyclophosphamide neurotoxicity, although it may have neurotoxic effects. Clarification of the possible neurotoxic/neuroprotective effects of empagliflozin would be beneficial for diabetic cancer patients who are receiving cyclophosphamide chemotherapy and empagliflozin together.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.